毒扁豆碱的安全性与有效性:一项10年回顾性综述
该回顾性队列研究纳入2003至2012年间报告至区域中毒中心系统、因逆转抗胆碱能中毒综合征而接受毒扁豆碱治疗的住院患者,共191例符合纳入标准。按主要摄入物分层,非苯海拉明抗组胺药、抗精神病药和三环类抗抑郁药暴露患者应答率均为100%,抗胆碱能植物、苯海拉明和复方制剂部分应答。95.3%患者无记录的不良反应,呕吐2.1%、QTc延长1.0%、癫痫发作1.0%,单例死亡发生在给药后6小时。平均初始总剂量1.0至1.75 mg,57.6%入住ICU,18.8%直接从急诊出院。
要点
- 191例抗胆碱能谵妄患者中,95.3%(182例)无记录的不良反应,呕吐2.1%、QTc延长1.0%、癫痫发作1.0%。
- 平均初始总剂量范围为1.0至1.75 mg,作者结论认为剂量低于2 mg时改善或缓解谵妄且安全性良好。
- 非苯海拉明抗组胺药(n=14)、抗精神病药(n=4)、三环类抗抑郁药(n=3)暴露患者应答率均为100%。
- 抗胆碱能植物应答率68.7%(46/67,OR 0.70,95%CI 0.36-1.35),苯海拉明64.2%(43/56,OR 1.30,95%CI 0.63-2.68),复方制剂80%(8/10,OR 1.48,95%CI 0.30-7.24)。
- 74.3%(142例)单用毒扁豆碱,其中8.4%(16例)直接从急诊出院;总体18.8%(36例)直接从急诊出院,57.6%(110例)入住ICU。
适用人群与场景
- 2003至2012年间报告至区域中毒中心系统、因逆转抗胆碱能中毒综合征而接受毒扁豆碱治疗的住院患者,共191例符合纳入标准。
处置流程与药物剂量
- 平均初始总剂量范围为1.0至1.75 mg,作者结论认为剂量低于2 mg时给药可改善或缓解抗胆碱能谵妄。
研究设计与关键结果
- 回顾性队列研究,纳入191例接受毒扁豆碱逆转抗胆碱能谵妄的住院患者,按主要摄入物分层。
- 非苯海拉明抗组胺药(n=14)、抗精神病药(n=4)、三环类抗抑郁药(n=3)暴露患者应答率均为100%。
- 抗胆碱能植物应答率68.7%(46/67,OR 0.70,95%CI 0.36-1.35),苯海拉明64.2%(43/56,OR 1.30,95%CI 0.63-2.68),复方制剂80%(8/10,OR 1.48,95%CI 0.30-7.24)。
- 142例(74.3%)单用毒扁豆碱,其中16例(8.4%)直接从急诊出院;总体36例(18.8%)直接从急诊出院,110例(57.6%)入住ICU。
- 182例(95.3%)无记录的不良反应;4例(2.1%)呕吐,2例(1.0%)QTc延长,2例(1.0%)癫痫发作;单例死亡发生在毒扁豆碱给药后6小时。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,毒扁豆碱用于逆转抗胆碱能谵妄在剂量低于2 mg时安全性良好,常可改善或缓解谵妄。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Physostigmine has long been recognized as an antidote to reverse anticholinergic delirium. However, its effectiveness, safety profile, and dosing have been disputed.
OBJECTIVES: To describe effectiveness, adverse events, and dosing associated with the use of physostigmine to reverse anticholinergic delirium.
METHODS: A retrospective cohort study of hospitalized patients reported to a regional poison center system between 2003 and 2012 who received physostigmine to reverse an anticholinergic toxidrome. Data extraction of a priori defined variables were recorded with concurrence of investigators. The cases were stratified by the primary ingestant as the presumed causative agent and associations for response were performed using odds ratios (ORs), 95% confidence intervals (CI's), and p values.
RESULTS: Of the 1422 cases identified, 191 met the inclusion criteria. Patients exposed to non-diphenhydramine antihistamines (n = 14), antipsychotics (n = 4), and tricyclic antidepressants (n = 3) had 100% response to physostigmine, whereas anticholinergic plants (n = 46/67; 68.7%, OR: 0.70; CI: 0.36-1.35), diphenhydramine (n = 43/56; 64.2%, OR: 1.30; CI: 0.63-2.68), and combination products (n = 8/10; 80%, OR: 1.48; CI: 0.30-7.24) had partial response rates. Of the included patients, 142 (74.3%) were treated with physostigmine alone, and 16 (8.4%) of these patients were discharged directly from the emergency department (ED).
DISCUSSION: Most patients, 182 (95.3%), had no documented adverse effects. Four patients (2.1%) experienced emesis, two experienced QTc prolongation (1.0%), and two experienced seizures (1.0%). There was a single fatality 6 h after physostigmine administration. Average initial total doses of physostigmine ranged from 1.0 to 1.75 mg. Most patients were admitted to the ICU (n = 110; 57.6%), however, 36 (18.8%) patients were discharged directly from the ED.
CONCLUSIONS: In this retrospective cohort study, physostigmine administration to reverse anticholinergic delirium had a good safety profile, and often improved or resolved anticholinergic delirium when administered in doses less than 2 mg.
参考来源
- Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review<sup/>. Clin Toxicol (Phila). 2017. PMID: 28703024. doi:10.1080/15563650.2017.1342828
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。